Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

COVID-19 Map Tracker | COVID-19 News Features


Globe NewsWire News Distribution Service


SAN FRANCISCO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now.

Class Period: Dec. 21, 2020 – Aug. 17, 2021
Lead Plaintiff Deadline: Oct. 18, 2021
Visit: www.hbsslaw.com/investor-fraud/SESN
Contact An Attorney Now: This email address is being protected from spambots. You need JavaScript enabled to view it.
                                                844-916-0895

Sesen Bio, Inc. (SESN) Securities Fraud Class Action:

The complaint alleges that Defendants misrepresented clinical trial data for Sesen’s lead product candidate Vicineum for the treatment of certain non-muscle invasive bladder cancer.

Specifically, Defendants concealed that: (1) the company’s clinical trial for Vicineum had more than 2,000 protocol violations, including 215 classified as “major,” (2) three of the company’s clinical investigators were found guilty of “serious noncompliance,” including backdating data, (3) the company submitted tainted data for Vicineum to the FDA, (4) the company’s clinical trials showed that Vicineum leaked out into the body and caused serious side effects and increased risks for fatal liver injury.

The truth began to emerge on Aug. 13, 2021, when Sesen announced the FDA did not approve the BLA in its present form and sought additional clinical/statistical data.

Then, on Aug. 16, 2021, the company revealed it needed to conduct an additional clinical trial to provide the FDA with additional efficacy and safety data.

Finally, on Aug. 18, 2021, STAT published an article entitled “Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show.” STAT cited hundreds of pages of internal documents and three people familiar with the matter reported the Vicineum clinical trial “was marked by thousands of violations of study rules, damning investigator conduct, and worrying signs of toxicity the company did not publicly disclose.”

These events sent the price of Sesen shares sharply lower.

“We’re focused on investors’ losses and proving Sesen lied to them about the prospects for Vicineum,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Sesen and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Sesen should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email This email address is being protected from spambots. You need JavaScript enabled to view it..

About Hagens Berman
Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895


Press Release: SESN 4-DAY DEADLINE ALERT: Hagens Berman Alerts Sesen Bio (SESN) Investors to OCT. 18TH LEAD PLAINTIFF DEADLINE in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys Now


Posted: 2021-10-14 14:06:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



Related News Stories From The Web And More

Related Bing News Search Results

Press Release: SESN 4-DAY DEADLINE ALERT: Hagens Berman Alerts Sesen Bio (SESN) Investors to OCT. 18TH LEAD PLAINTIFF DEADLINE in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys Now - Newscast

(SESN) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Sesen Bio, Inc. Class Action Lawsuit

Sat, 16 Oct 2021 07:08:00 GMT Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Sesen Bio, Inc. ("Sesen Bio” or the "Company") (NASDAQ: SESN). The class ...

SESEN BIO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sesen Bio, Inc. and Encourages Investors to Contact ...

Fri, 15 Oct 2021 22:00:00 GMT Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed aga ...

SESEN BIO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sesen Bio, Inc. and Encoura

Fri, 15 Oct 2021 18:00:00 GMT Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Sesen Bio, Inc. (“Sesen Bio” or the “Company”) ...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sesen Bio, Inc. (SESN)

Fri, 15 Oct 2021 10:10:00 GMT The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sesen Bio, Inc. (SESN) ...

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action ...

Fri, 15 Oct 2021 10:03:00 GMT Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2021 deadline to file a lead plaintiff motion ...

Related News Story Videos From Youtube



Blow Us A Whistle